Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(1):87–93. doi: 10.1038/bjc.1997.14

p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?

D N Poller 1, K J Baxter 1, N A Shepherd 1
PMCID: PMC2222690  PMID: 9000603

Abstract

The expression of the p53 and Rb1 proteins was examined in an unselected consecutive series of 250 primary operable colorectal carcinomas with a mean follow-up of 4.3 years (range 43-77 months). The overall cancer-specific mortality was 34.8%, with 87 cancer deaths and 35 deaths as the result of other causes. Expression of p53 protein was identified in 152 of 250 (60.8%) cases, with expression of Rb1 protein in 207 of 250 (82.8%) cases. There was no association of p53 or Rb protein expression with patient age, sex, tumour site, tumour size, tumour type, tumour grade, peritumoral fibrosis, tumour lymphocytic infiltrate, nature of the tumour margin, extramural vascular invasion, number of lymph nodes or high apical lymph node involved or local peritoneal infiltration by tumour, Dukes' stage or Jass group. There was no difference in overall survival or recurrence-free survival for those cases that showed p53 expression or Rb1 protein expression compared with those cases showing absence of p53 or Rb1 protein expression, although patients with tumours showing aberrant (reduced) Rb1 protein expression demonstrated shorter recurrence-free survival and overall survival. The effect of 'aberrant' Rb1 protein expression and shorter recurrence-free and overall survival did not, however, achieve independent statistical significance. The results from this study would suggest that expression of p53 and Rb1 proteins does not appear be useful in determining the prognosis of operable colorectal cancer.

Full text

PDF
87

Images in this article

89Figure 1
on p.89
90Figure 3
on p.90

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auvinen A., Isola J., Visakorpi T., Koivula T., Virtanen S., Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer. 1994 Aug;70(2):293–296. doi: 10.1038/bjc.1994.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baas I. O., Mulder J. W., Offerhaus G. J., Vogelstein B., Hamilton S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994 Jan;172(1):5–12. doi: 10.1002/path.1711720104. [DOI] [PubMed] [Google Scholar]
  3. Baas I. O., van den Berg F. M., Mulder J. W., Clement M. J., Slebos R. J., Hamilton S. R., Offerhaus G. J. Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol. 1996 Mar;178(3):264–267. doi: 10.1002/(SICI)1096-9896(199603)178:3<264::AID-PATH485>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  4. Bell S. M., Scott N., Cross D., Sagar P., Lewis F. A., Blair G. E., Taylor G. R., Dixon M. F., Quirke P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993 Jan;104(1):57–64. doi: 10.1016/0016-5085(93)90835-z. [DOI] [PubMed] [Google Scholar]
  5. Bertorelle R., Esposito G., Del Mistro A., Belluco C., Nitti D., Lise M., Chieco-Bianchi L. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol. 1995 Apr;19(4):463–471. doi: 10.1097/00000478-199504000-00008. [DOI] [PubMed] [Google Scholar]
  6. Cance W. G., Brennan M. F., Dudas M. E., Huang C. M., Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med. 1990 Nov 22;323(21):1457–1462. doi: 10.1056/NEJM199011223232105. [DOI] [PubMed] [Google Scholar]
  7. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  8. Goh H. S., Chan C. S., Khine K., Smith D. R. p53 and behaviour of colorectal cancer. Lancet. 1994 Jul 23;344(8917):233–234. doi: 10.1016/s0140-6736(94)93000-7. [DOI] [PubMed] [Google Scholar]
  9. Hamelin R., Laurent-Puig P., Olschwang S., Jego N., Asselain B., Remvikos Y., Girodet J., Salmon R. J., Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 1994 Jan;106(1):42–48. doi: 10.1016/s0016-5085(94)94217-x. [DOI] [PubMed] [Google Scholar]
  10. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990 Mar 24;335(8691):675–679. doi: 10.1016/0140-6736(90)90801-b. [DOI] [PubMed] [Google Scholar]
  11. Kern S. E., Pietenpol J. A., Thiagalingam S., Seymour A., Kinzler K. W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992 May 8;256(5058):827–830. doi: 10.1126/science.1589764. [DOI] [PubMed] [Google Scholar]
  12. Kocialkowski S., Pezzella F., Morrison H., Jones M., Laha S., Harris A. L., Mason D. Y., Gatter K. C. Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol. 1995 Jan;89(1):55–60. doi: 10.1111/j.1365-2141.1995.tb08911.x. [DOI] [PubMed] [Google Scholar]
  13. Lemoine N. R. Molecular biology of breast cancer. Ann Oncol. 1994;5 (Suppl 4):31–37. doi: 10.1093/annonc/5.suppl_4.s31. [DOI] [PubMed] [Google Scholar]
  14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  15. McKee P. H., Hobbs C., Hall P. A. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology. 1993 Oct;23(4):377–379. doi: 10.1111/j.1365-2559.1993.tb01223.x. [DOI] [PubMed] [Google Scholar]
  16. McManus D. T., Yap E. P., Maxwell P., Russell S. E., Toner P. G., McGee J. O. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol. 1994 Nov;174(3):159–168. doi: 10.1002/path.1711740304. [DOI] [PubMed] [Google Scholar]
  17. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 1990 Aug 24;62(4):671–680. doi: 10.1016/0092-8674(90)90113-s. [DOI] [PubMed] [Google Scholar]
  18. Mulder J. W., Baas I. O., Polak M. M., Goodman S. N., Offerhaus G. J. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer. 1995 Jun;71(6):1257–1262. doi: 10.1038/bjc.1995.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nathanson S. D., Linden M. D., Tender P., Zarbo R. J., Jacobsen G., Nelson L. T. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum. 1994 Jun;37(6):527–534. doi: 10.1007/BF02050985. [DOI] [PubMed] [Google Scholar]
  20. Nylander K., Nilsson P., Mehle C., Roos G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer. 1995 Apr;71(4):826–830. doi: 10.1038/bjc.1995.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Remvikos Y., Tominaga O., Hammel P., Laurent-Puig P., Salmon R. J., Dutrillaux B., Thomas G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 1992 Oct;66(4):758–764. doi: 10.1038/bjc.1992.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Scott N., Sagar P., Stewart J., Blair G. E., Dixon M. F., Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer. 1991 Feb;63(2):317–319. doi: 10.1038/bjc.1991.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shepherd N. A., Baxter K. J., Love S. B. Influence of local peritoneal involvement on pelvic recurrence and prognosis in rectal cancer. J Clin Pathol. 1995 Sep;48(9):849–855. doi: 10.1136/jcp.48.9.849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sherr C. J. Growth factor-regulated G1 cyclins. Stem Cells. 1994;12 (Suppl 1):47–57. [PubMed] [Google Scholar]
  25. Smith M. L., Chen I. T., Zhan Q., Bae I., Chen C. Y., Gilmer T. M., Kastan M. B., O'Connor P. M., Fornace A. J., Jr Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 1994 Nov 25;266(5189):1376–1380. doi: 10.1126/science.7973727. [DOI] [PubMed] [Google Scholar]
  26. Starzynska T., Bromley M., Ghosh A., Stern P. L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer. 1992 Sep;66(3):558–562. doi: 10.1038/bjc.1992.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sun X. F., Carstensen J. M., Stål O., Zhang H., Nilsson E., Sjödahl R., Nordenskjöld B. Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virchows Arch A Pathol Anat Histopathol. 1993;423(6):443–448. doi: 10.1007/BF01606533. [DOI] [PubMed] [Google Scholar]
  28. Sun X. F., Carstensen J. M., Zhang H., Stål O., Wingren S., Hatschek T., Nordenskjöld B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 1992 Dec 5;340(8832):1369–1373. doi: 10.1016/0140-6736(92)92558-w. [DOI] [PubMed] [Google Scholar]
  29. Vojtesek B., Bártek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992 Jul 6;151(1-2):237–244. doi: 10.1016/0022-1759(92)90122-a. [DOI] [PubMed] [Google Scholar]
  30. Yamaguchi A., Kurosaka Y., Fushida S., Kanno M., Yonemura Y., Miwa K., Miyazaki I. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer. 1992 Dec 15;70(12):2778–2784. doi: 10.1002/1097-0142(19921215)70:12<2778::aid-cncr2820701209>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  31. Yamaguchi A., Nakagawara G., Kurosaka Y., Nishimura G., Yonemura Y., Miyazaki I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer. 1993 Aug;68(2):399–402. doi: 10.1038/bjc.1993.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yamamoto H., Monden T., Ikeda K., Izawa H., Fukuda K., Fukunaga M., Tomita N., Shimano T., Shiozaki H., Monden M. Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer. Br J Cancer. 1995 Jun;71(6):1231–1236. doi: 10.1038/bjc.1995.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zeng Z. S., Sarkis A. S., Zhang Z. F., Klimstra D. S., Charytonowicz E., Guillem J. G., Cordon-Cardo C., Cohen A. M. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol. 1994 Oct;12(10):2043–2050. doi: 10.1200/JCO.1994.12.10.2043. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES